冠昊生物(300238) - 2024 Q3 - 季度财报

Financial Performance - Q3 2024 revenue was ¥88,437,338.79, a decrease of 9.88% year-over-year[3] - Net profit attributable to shareholders was ¥7,687,894.20, down 26.98% compared to the same period last year[3] - Net profit excluding non-recurring items was ¥1,311,942.87, a significant decline of 87.55% year-over-year[3] - Total operating revenue for Q3 2024 was CNY 278,135,520.40, a decrease of 9.96% compared to CNY 308,949,013.47 in Q3 2023[13] - Net profit for Q3 2024 was CNY 20,658,923.30, a decline of 45.9% from CNY 38,132,984.55 in Q3 2023[14] - The company reported a basic earnings per share of ¥0.03, a decrease of 25.00% from the same period last year[3] - The company reported a basic earnings per share of CNY 0.10 for Q3 2024, down from CNY 0.16 in the same quarter last year[15] Assets and Liabilities - Total assets increased to ¥730,320,039.53, reflecting a growth of 7.62% from the end of the previous year[3] - The company's total assets increased to CNY 730,320,039.53 in Q3 2024, up from CNY 678,594,899.40 in Q3 2023, representing a growth of 7.63%[12] - Total liabilities rose to CNY 259,246,229.72, compared to CNY 222,334,653.65 in the previous year, marking an increase of 16.61%[12] - The total non-current liabilities increased to CNY 94,958,477.37, up from CNY 49,618,436.92 in Q3 2023, indicating an increase of 91.1%[12] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,274[8] - The largest shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., holds 20.76% of the shares, totaling 55,044,822 shares[8] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥32,342,033.71, down 46.00% year-over-year[3] - Operating cash inflow for the current period was $323,070,746.17, a decrease of 3.5% from $334,839,021.52 in the previous period[16] - Net cash flow from operating activities was $290,728,712.46, compared to $274,941,449.79 in the previous period, reflecting an increase of 5.7%[17] - Cash outflow from investing activities totaled $60,133,403.09, significantly higher than $24,036,700.71 in the previous period, indicating increased investment activity[17] - The company received $72,000,000.00 in cash from borrowings, up from $25,500,000.00 in the previous period, indicating increased leverage[17] Expenses - Total operating costs for Q3 2024 were CNY 249,921,949.86, down from CNY 258,011,428.97 in the same period last year, reflecting a reduction of 3.67%[13] - Research and development expenses for Q3 2024 were CNY 28,093,493.13, a decrease of 8.01% from CNY 30,545,444.76 in Q3 2023[14] - The company experienced a decrease in sales expenses, which were CNY 118,255,574.23 in Q3 2024, down from CNY 124,263,910.25 in Q3 2023, reflecting a reduction of 4.03%[14] Other Income and Financial Activities - Financial expenses decreased by 72.78% to ¥647,420.35 due to a reduction in total current loans[6] - Other income increased by 81.07% to ¥8,901,376.79, attributed to higher government subsidies received[6] - Investment income turned positive at ¥805,725.68, a 122.73% improvement from a loss in the previous year[6] - The company reported a cash inflow of $1,075,517.00 from tax refunds, contributing to the overall cash flow[16] Shareholder Actions and Market Position - The controlling shareholder plans to auction off a total of 30,650,000 shares, which are non-restricted shares[9] - The company has not reported any changes in the top 10 shareholders due to securities lending activities[9] - The company has not disclosed any new product developments or market expansion strategies in the current report[9] - There are no significant mergers or acquisitions reported in the current financial period[9]